Metronidazole Vaginal Gel 0.75% (Zidoval TM) for Suppresion of Recurrent Bacterial Vaginosis (BV): A Pilot Clinical TrialAdil Isaac* and Soad El Muthre
Prince Sultan Military Medical City (PSCC), Riyadh11393, KSA
- *Corresponding Author:
- Adil Isaac
Prince Sultan Military Medical City (PSCC)
PO Box 366428, Riyadh11393, KSA
Tel: 0557 919695
E-mail: [email protected]
Received date: March 18, 2015; Accepted date: April 21, 2015; Published date: April 28, 2015
Citation: Isaac A, El Muthre Ss (2015) Metronidazole Vaginal Gel 0.75% (Zidoval™) for Suppresion of Recurrent Bacterial Vaginosis (BV): A Pilot Clinical Trial. Clin Microbiol 4:196. doi:10.4172/2327-5073.1000196
Copyright: © 2015 Isaac A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objectives: A pilot efficacy and tolerability trial of suppressive metronidazole vaginal gel in reducing recurrent symptomatic relapses of bacterial vaginosis (BV). Study design: A prospective open labeled study. Women with recurrent BV were assigned to metronidazole gel 3 times monthly for 24 weeks. The mean episodes of relapses of recurrence of BV after metronidazole suppression was compared to historical mean obtained from the same participants by a paired-sample T test. An exit interview was used to record patient satisfaction. Results: The mean symptomatic relapses of BV was 0.44 (SD1.09). Historically, participants had a mean of 6.5 (SD3.09) by clinical or laboratory criteria, and a mean of 3.75 (1.06) by laboratory criteria only. Compared with each of the historical means by paired-sample T test, the difference is significant in both at P<0.0001. Adverse effects were uncommon. Conclusions: Suppressive therapy of BV with metronidazole gel for 3 days after the menstrual cycle resulted in significant reduction in symptomatic relapses. Adverse effects were uncommon. A randomized controlled trial is needed to further validate these results.